Evidence map›Paper›PMID 39240097›Full record

ArticleAntimicrobial agents and chemotherapy2024

Polymyxins retain

Jennifer Rubio, Jun Yan, Sarah Miller, Jiaqi Cheng, Rachel Li, Zac Builta, Kari Aoyagi, Mark Fisher, Rosemary She, Brad Spellberg and 1 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer RubioDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.ORCID 0009-0006-3789-6551
Jun YanDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
Sarah MillerDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
Jiaqi ChengDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
Rachel LiDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
Zac BuiltaDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
Kari AoyagiDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.
Mark FisherDepartment of Pathology, University of Utah, Salt Lake City, Utah, USA.
Rosemary SheDepartment of Pathology, Keck School of Medicine of USC, Los Angeles, California, USA.
Brad SpellbergLos Angeles General Medical Center, Los Angeles, California, USA.
Brian LunaDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.ORCID 0000-0001-6718-4551

Funding

MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7M
Characterization of Rifabutin Therapy Against Antibiotic-Resistant BacteriaR01AI139052 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LUNA, BRIAN MICHAEL · 2018 to 2021
$2.4M
Identifying Synergistic Rifabutin-Containing Combinations Against A. baumanniiR01AI179046 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Brian Michael Luna · 2024 to 2026
$1.4M
2016 SETAC Asia/Pacific ConferenceR13ES027302 · NIEHS · SOCIETY/ENVIRONMENTAL TOXICOLOGY/CHEM · PI MENZIE, CHARLES · 2016 to 2016
$6k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 2RO1AI130060HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI139052HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) RO1AI179046MOHW | Food and Drug Administration (FDA) 75F40122C00138NIAID NIH HHS R01 AI130060NIAID NIH HHS R01 AI139052NIAID NIH HHS R01 AI179046NIEHS NIH HHS 27302C0138
6 · The paper itself

Abstract

The emergence of plasmid-mediated resistance threatens the efficacy of polymyxins as the last line of defense against pan-drug-resistant infections. However, we have found that using Mueller-Hinton II (MHII), the standard minimum inhibitory concentration (MIC) medium, results in MIC data that are disconnected from

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsColistinMicrobial Sensitivity TestsPolymyxin BPolymyxinsAnimalsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialHumansMiceAnti-Bacterial AgentsColistinPolymyxin BPolymyxinsAcinetobacterantibiotic resistancecolistinpolymyxins

Identifiers

PMID39240097
PMCPMC11459914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.